METHOD FOR PREDICTING RADIOIODINE THERAPY FOR GRAVES' DISEASE Russian patent published in 2023 - IPC G01N33/49 G01N33/564 

FIELD: medicine; endocrinology.

SUBSTANCE: invention can be used to predict the effectiveness of radioiodine therapy in the treatment of Graves' disease. Perform blood sampling and testing. The percentage of B-lymphocytes — CD19⁺ and activated T-helpers — CD3⁺CD4⁺CD25⁺CD45⁺ is determined in patients before radioiodine therapy (RIT) using the flow cytometry method. Then the value of the T-helper regulation coefficient (THR) is calculated, which is the ratio of the percentage of activated T-helpers to the percentage of B-lymphocytes. If the TCR value is below 0.105, the development of persistent post-radiation hypothyroidism is predicted within 6 months after RIT. If the TCR value is equal to or exceeds 0.105, the absence of a persistent decrease in thyroid function — hypothyroidism is predicted in the outcome of radionuclide treatment within 6 months after RIT.

EFFECT: informative early prediction of the effectiveness of RIT in Graves' disease by determining the percentage of B-lymphocytes and activated T-helpers in patients before RIT using flow cytometry.

1 cl, 4 ex